Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ1R Agonists/HDAC Inhibitor Dual-Acting Compounds - PubMed
3 hours ago
- #neurodegenerative diseases
- #dual-acting compounds
- #tau protein
- Study explores dual-acting compounds combining σ1R agonists and HDAC inhibitors to target tau protein neurotoxicity in Alzheimer's disease.
- Compounds 2d and 3a showed high σ1R affinity, reduced tau aggregation and phosphorylation, and improved tau solubility.
- Compound 2d exhibited better chemical stability and longer half-life compared to 3a.
- In vivo tests confirmed σ1R agonist profile by reversing effects of σ1R antagonist BD-1063.
- Dual-action approach targeting HDAC and σ1R pathways shows promise for treating tauopathies.
- Further optimization and clinical evaluation needed for these multimodal therapies.